This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Trisomy 21, meiotic nondisjunction21삼염색체증, 감수분열비분리

Contents and basic classification information
A. Classification codes ICD-10: Q90.0 / Special Copayment Reduction: V159 / Re-certification cycle: 5 years B. Synonyms None
C. Adult onset Many adult complications, including early Alzheimer's disease, hypothyroidism, premature menopause, and cognitive decline
1. History 2. Causes 3. Genetics 4. General epidemiology
5. Pathophysiology 6. Symptoms 7. Signs 8. Screening
9. Diagnosis 10. Treatment 11. Prognosis 12. Prevention
13. References

1. History

The history of Down syndrome can be divided into three stages: clinical description, cytogenetic identification, and molecular biological understanding. In 1866, the British physician John Langdon Down published the paper "Observations on an Ethnic Classification of Idiots," describing a group of patients with a characteristic facial phenotype and intellectual disability observed at the Earlswood Asylum in Surrey. Down described them in the language of ethnic taxonomy and used the inappropriate term "Mongolism," but the description itself is regarded as the first clear establishment of this condition as an independent entity.

In the 1930s–1950s, environmental factor hypotheses were raised, but no genetic basis was identified. The decisive turning point was 1959, when the French cytogeneticist Jérôme Lejeune and his colleagues Marthe Gautier and Raymond Turpin first confirmed that the somatic cells of patients with Down syndrome have 3 rather than 2 copies of chromosome 21. This is recorded as a landmark event in the history of human medical genetics, the first achievement proving that trisomy is the cause of a human disease.

In the 1960s, the three cytogenetic types of trisomy—complete trisomy, translocation, and mosaicism—were each distinguished. In 1966, the WHO unified the official name as "Down syndrome" and abandoned the term "Mongolism." In the 1970s, prenatal diagnosis through amniocentesis was introduced into clinical practice, laying the foundation for screening tests for older pregnant women.

In the 1980s, precursor technologies of fluorescence in situ hybridization (FISH) and noninvasive prenatal testing (NIPT) began to be developed, and in the 1990s the Down Syndrome Critical Region (DSCR) was narrowed to the 21q22.13 location on the long arm of chromosome 21. Since the 2000s, with the clinical application of next-generation sequencing (NGS)-based NIPT, highly sensitive prenatal screening using cell-free fetal DNA in the blood has become possible. At present, the molecular understanding of the mechanism of meiotic nondisjunction, especially the cohesin complex aging hypothesis, is being actively studied.


2. Causes

Down syndrome designated by the Q90.0 code is caused by meiotic nondisjunction. This is the mechanism in which chromosome 21 fails to separate normally during gametogenesis, forming an abnormal gamete with 24 chromosomes (including two copies of chromosome 21), and when this is fertilized by a normal gamete (23 chromosomes), the zygote has 3 copies of chromosome 21.

Maternal-origin meiotic nondisjunction

About 88–95% of all standard trisomy 21 results from maternal meiotic errors. Of these, about 75–80% arise from meiosis I (MI) nondisjunction and about 20–25% from meiosis II (MII) nondisjunction. MI nondisjunction is the failure of homologous chromosomes to separate in anaphase I, and MII nondisjunction is the failure of sister chromatids to separate in anaphase II.

Paternal-origin meiotic nondisjunction

The remaining about 5–10% is of paternal origin. Both paternal MI and MII nondisjunction are observed, but overall the paternal contribution is markedly lower than the maternal. Paternal MI errors are associated with failure of homologous chromosome synapsis or lack of crossover during spermatogenesis.

Cohesin complex aging and the maternal age effect

The phenomenon that the risk of meiotic nondisjunction rises exponentially with increasing maternal age is explained by the special cell-cycle arrest characteristics of oocytes. A woman's primary oocytes enter prophase I of meiosis during fetal life and then remain in dictyate arrest for decades. During this period, the cohesin protein complex (SMC1β, SMC3, REC8, etc.) that holds sister chromatids together is gradually degraded or loses function, reducing cohesion at crossover sites. As a result, kinetochore alignment errors and nondisjunction increase when meiosis resumes.

Abnormal recombination patterns

When nondisjoined chromosomes 21 are analyzed by origin, crossover frequency tends to be reduced compared with normally segregated chromosomes, or the crossover location tends to be biased toward the pericentromeric or distal region. In MI nondisjunction, cases with no crossover at all on chromosome 21 (achiasmate bivalent) are observed especially often. This lack of recombination weakens bivalent stability and promotes nondisjunction.


3. Genetics

The karyotype of the Q90.0 type is 47,XX,+21 or 47,XY,+21. It is distinguished from the translocation form (Q90.2) in that the third chromosome 21 exists as a free, unattached chromosome and is not fused to another chromosome. It also differs from the mosaic form (Q90.1) in that all cells show the same karyotype.

Gene content of chromosome 21

Chromosome 21 is one of the smallest human autosomes, containing about 230–250 protein-coding genes in about 47 Mb of euchromatic sequence. Genes central to the Down syndrome phenotype include APP (amyloid precursor protein, associated with Alzheimer's disease), SOD1 (Cu/Zn superoxide dismutase), DYRK1A (dual-specificity tyrosine phosphorylation-regulated kinase 1A), RCAN1 (Regulator of calcineurin 1), COL6A1/A2 (type 6 collagen), ETS2 (transcription factor), and the DSCR1–10 gene group.

Gene dosage imbalance

Because of the trisomy, chromosome 21 genes are expressed at a dosage of three, a 1.5-fold increase over the normal two. This 1.5-fold overexpression causes perturbation across the protein interaction network and gives rise to the multisystem phenotype of Down syndrome. The key to the pathophysiology of trisomy is that it is not a simple excess of genes but that a quantitative change leads to a qualitative change.

Heterodisomy by origin and isozyme analysis

DNA polymorphic markers and single nucleotide polymorphism (SNP) analysis can determine the parental origin of the extra chromosome 21. In maternal MI nondisjunction, all three chromosomes 21 have different haplotypes, so heterodisomy appears, and in MII nondisjunction, the two added maternal chromosomes show the same haplotype, so isodisomy appears. This analysis is used to determine the mechanism of nondisjunction.

Recurrence risk

In standard trisomy 21 due to sporadic nondisjunction, the recurrence risk is generally low, but it is known that when there was a trisomy in a previous pregnancy, there is an additional risk of about 1% after age adjustment. When the parental karyotypes are normal, unlike the recurrence risk of the translocation form, most cases are sporadic, so parental chromosome testing is performed to exclude secondary trisomy or translocation.


4. General epidemiology

Down syndrome is the most common chromosomal abnormality, occurring worldwide at a frequency of 1 in 700–800 births. Of these, about 95% are standard trisomy 21 (Q90.0 and Q90.9), with the translocation form (Q90.2) accounting for about 3–4% and the mosaic form (Q90.1) for about 1–2%. The prevalence of Down syndrome is similar in most countries worldwide, including Korea, with no large differences by ethnicity.

Maternal age and incidence

The incidence of trisomy 21 shows a strong positive correlation with maternal age. It rises sharply, from about 1/1,500 in mothers in their early twenties, to about 1/900 at age 30, about 1/350 at age 35, about 1/100 at age 40, and about 1/30 at age 45 or older. Nevertheless, more than half of Down syndrome births occur in mothers under age 35, because the absolute number of young pregnant women is far greater than the number of older pregnant women.

Effect of prenatal screening and diagnosis

Since the 2010s, when NIPT became widespread, the prenatal diagnosis rate has risen greatly in high-income countries, but decisions on continuing the pregnancy after diagnosis vary according to the individual and the social and cultural context. In Korea, maternal serum screening was introduced in the 1980s, and with the spread of NIPT it is now used as a primary screening tool. According to Health Insurance Review & Assessment Service (HIRA) data in Korea, Down syndrome is one of the diseases with a large number of registrations among rare disease Special Copayment Reduction registration targets (V159).

Trends in survival and prevalence

With advances in medical technology, the life expectancy of patients with Down syndrome has improved greatly. In the 1960s most died before age 10, but now, with advances in corrective surgery for congenital heart disease, infection prevention, and management of thyroid disease, average life expectancy has extended to 60 years or more. Accordingly, the number of adult patients with Down syndrome is increasing, and management of aging-related complications such as Alzheimer's disease has emerged as an important task.


5. Pathophysiology

Q90.0 Down syndrome arises from an error in cell division called meiotic nondisjunction during gamete formation. The cell biological and molecular understanding of this mechanism has advanced rapidly over the past several decades.

Molecular mechanism of meiosis I (MI) nondisjunction

In normal meiosis, homologous chromosome pairs (bivalents) are mechanically linked through homologous recombination (crossover) in prophase I of meiosis. The chiasmata formed at these crossover sites keep the homologous chromosome pair stably together until spindle traction acts in anaphase I. MI nondisjunction of chromosome 21 occurs when bivalent stability collapses because of a reduced number or abnormal position of chiasmata. When the cohesin complex (SMC1β-SMC3-REC8-STAG3) is weakened, cohesion is lost particularly in the pericentromeric region, and the surveillance function of the spindle assembly checkpoint (SAC) also declines in aged oocytes.

Molecular mechanism of meiosis II (MII) nondisjunction

MII nondisjunction is the case in which the sister chromatids of a chromosome 21 univalent, normally separated in MI, fail to separate in meiosis II. Loss of cohesin binding at the MII stage (in particular, failure of STAG3-dependent maintenance of pericentromeric cohesin) is proposed as the main cause. Aneuploid zygotes generated by MII nondisjunction show an SNP isodisomy pattern distinct from that of MI nondisjunction.

Effect of trisomy 21 on development

From immediately after fertilization, the extra chromosome 21 causes gene dosage imbalance throughout the embryo. Overexpression of DYRK1A suppresses neural progenitor cell proliferation and accelerates the cell cycle, causing a reduced number of cortical neurons. Overexpression of RCAN1 suppresses calcineurin signaling and impairs synaptic plasticity and memory formation. Overexpression of APP is the direct cause of increased amyloid-β production and increased risk of early Alzheimer's disease. Overexpression of SOD1 is proposed to cause an imbalance in the regulation of oxidative stress and to promote apoptosis.

Mechanism of abnormal cardiac development

Overexpression of the COL6A1 and COL6A2 genes on chromosome 21 affects development of the endocardial cushion and increases the frequency of congenital heart disease such as atrioventricular septal defect (AVSD). Overexpression of the ERG and ETS2 transcription factors also perturbs the gene network of cardiac morphogenesis.


6. Symptoms

Down syndrome presents with multisystem clinical symptoms, including a characteristic facial phenotype, intellectual disability, congenital malformations, endocrine abnormalities, and premature aging. The severity of symptoms varies by individual patient, but because standard trisomy (Q90.0) shows the same increase in gene dosage throughout the body, the overall phenotypic burden is large.

Central nervous system and cognitive function

Intellectual disability (ID) occurs in almost all patients, and IQ is mostly distributed in the range of 40–70 (mild to moderate intellectual disability). In language development, expressive language is markedly delayed compared with receptive language, and short-term auditory memory, processing speed, and executive function are particularly vulnerable. On the other hand, visuospatial memory, social cognition, and musical ability tend to be relatively preserved. Provoked seizures (epilepsy) may occur in childhood, and infantile spasms may also occur.

Musculoskeletal system and connective tissue

Generalized hypotonia is one of the most prominent early findings in the neonatal period and is a major cause of feeding difficulty and delayed motor development. Ligamentous laxity can cause hyperextensible joints, flat feet, scoliosis, and atlantoaxial instability (AAI). AAI is confirmed radiographically in about 15% of patients, and symptomatic AAI occurs in about 1–2% and can cause cervical cord compression symptoms (torticollis, abnormal upper limb movement, bladder dysfunction).

Gastrointestinal system

Gastrointestinal malformations such as duodenal atresia, esophageal stenosis, Hirschsprung disease, and gastroesophageal reflux disease (GERD) accompany at high frequency. Duodenal atresia occurs in about 2–5% of Down syndrome, and conversely Down syndrome accompanies about 20–30% of duodenal atresia. Chronic constipation is common in adults, and the incidence of celiac disease is higher than in the general population.

Immune and hematologic systems

Recurrent respiratory infections, otitis media, and skin infections are common, owing to immune vulnerabilities such as T-cell dysfunction, decreased NK cells, and reduced antibody responses. The risk of acute lymphoblastic leukemia (ALL) and acute megakaryoblastic leukemia (AMKL) is 10–20 times higher than in the general population, and transient abnormal myelopoiesis (TAM) in the neonatal period is observed in about 10%.


7. Signs

The clinical signs of Down syndrome appear as a characteristic pattern that an experienced clinician can recognize at the newborn examination, and cytogenetic confirmation is subsequently required.

Craniofacial signs

The craniofacial phenotype is characterized by upslanting palpebral fissures, epicanthal folds, Brushfield spots (white speckled spots at the periphery of the iris), a flat occiput (brachycephaly), a flat nasal bridge, a short nose, small ears (low-set, small, round), and a tendency for the tongue to protrude (relative macroglossia). The palate is narrow and high-arched, and dental abnormalities (hypoplasia, early eruption, malposition) are also common.

Hand, foot, and skin signs

Single palmar crease (simian crease) is known as a classic sign of Down syndrome but may also appear in about 1–4% of normal individuals. Clinodactyly of the 5th finger, a widened gap between the first and second toes (sandal gap), and abnormal dermatoglyphics (increased bilateral ulnar loops) are also characteristic. Dry skin, warts (verruca), seborrheic dermatitis, and alopecia areata are also common in adulthood.

Ophthalmologic signs

Refractive errors (myopia, hyperopia, astigmatism) are very common, and strabismus, nystagmus, amblyopia due to refractive error, cataract (congenital and early-onset), and corneal abnormalities (keratoconus) occur. Regular ophthalmologic examination is essential.

Cardiac auscultation findings

When congenital heart disease is present, a murmur, cyanosis during feeding, tachypnea, etc. may appear. The most common cardiac malformation in Down syndrome is atrioventricular septal defect (AVSD, about 40%), followed in order by ventricular septal defect (VSD), atrial septal defect (ASD), patent ductus arteriosus (PDA), and tetralogy of Fallot (ToF).

Growth indicators

Weight and height lie in the lower distribution on Down syndrome growth curves. A tendency toward obesity becomes prominent in adulthood, due to multiple factors such as decreased basal metabolic rate, hypothyroidism, and lack of exercise.


8. Screening

Screening tests for Down syndrome are divided into the prenatal stage and the neonatal/childhood stage. Screening during pregnancy is performed to identify high-risk groups and link them to confirmatory testing.

First-trimester combined screening

Risk is calculated by combining fetal nuchal translucency (NT) ultrasound performed at 11–13+6 weeks of gestation with maternal serum markers—pregnancy-associated plasma protein A (PAPP-A) and free β-human chorionic gonadotropin (free β-hCG). The detection rate is about 85–90% and the false-positive rate is about 5%. Because increased NT is associated with other chromosomal abnormalities and cardiac malformations as well as trisomy 21, additional testing is needed.

Second-trimester quad screen

At 15–20 weeks of gestation, maternal serum α-fetoprotein (AFP), β-hCG, unconjugated estriol (uE3), and inhibin A are measured. In Down syndrome, AFP and uE3 decrease and β-hCG and inhibin A increase. It has a detection rate of about 80% on its own, but at present it plays a supplementary role compared with first-trimester combined testing or NIPT.

Noninvasive prenatal testing (NIPT)

From 10 weeks of gestation, cell-free fetal DNA (cffDNA) in maternal blood is analyzed by next-generation sequencing to detect an increased proportion of chromosome 21. It shows very high accuracy, with sensitivity above 99% and specificity above 99.9% for trisomy 21. However, because NIPT is a screening test, a positive result must be confirmed by invasive confirmatory testing (chorionic villus sampling or amniocentesis). Causes of false positives include confined placental mosaicism, vanishing twin, and maternal malignancy.

Pediatric and adult monitoring items

After confirmation of Down syndrome, thyroid function tests (TSH, free T4) are recommended in the neonatal period, at 6 months, at 12 months, and annually thereafter. Hearing tests are performed every 6 months after neonatal hearing screening, and ophthalmologic examination is followed regularly after the first examination at 6 months to 1 year. Cervical spine radiography to evaluate atlantoaxial instability is performed before high-risk activities (sports, general anesthesia, neck surgery).


9. Diagnosis

Confirmation of Down syndrome is by cytogenetic testing. Karyotype analysis is essential to distinguish standard trisomy 21 (Q90.0), the translocation form (Q90.2), and mosaicism (Q90.1), which directly affects prognosis and genetic counseling.

G-banding karyotype analysis (Karyotyping)

In this standard cytogenetic method, 20 or more metaphase cells are analyzed. Peripheral blood lymphocytes from whole-blood culture are generally used, and chorionic villus or amniotic cells are used for prenatal diagnosis. The resolution is on the order of 5–10 Mb, and standard trisomy, translocation, and large structural abnormalities can all be identified. However, there are limits to detecting low-level mosaicism, so when clinically suspected, more cells are analyzed or FISH/chromosomal microarray is added.

Fluorescence in situ hybridization (FISH)

Using a chromosome 21-specific probe, the number of signals in each cell nucleus is counted. Interphase FISH can be performed without metaphase cells, and results can be obtained within hours, making it useful for rapid screening. Confirming the translocation form requires a translocation junction probe.

Chromosomal microarray (CMA) and SNP array

SNP-based CMA confirms trisomy with diagnostic efficiency equivalent to karyotype analysis and can also estimate the mosaic proportion and determine parental origin. It has the advantage of additionally detecting microdeletions/duplications not found on karyotype analysis. However, there are limits to detecting balanced translocations, so karyotype analysis is essential when the translocation form is suspected.

Prenatal confirmatory testing

Chorionic villus sampling (CVS, 10–13 weeks of gestation) allows early confirmation, and amniocentesis (15–20 weeks of gestation) has a lower risk of complications. Karyotype analysis, FISH, QF-PCR, and CMA can be applied with both methods. The pregnancy-related miscarriage risk is known to be about 0.5–1% for CVS and about 0.1–0.3% for amniocentesis.


10. Treatment

There is currently no treatment that corrects trisomy 21 itself. Treatment includes multidisciplinary management of accompanying malformations and complications, rehabilitation, and educational support.

Treatment of congenital heart disease

Atrioventricular septal defect (AVSD) is the most common; the principle is early surgical correction after diagnosis by echocardiography. Corrective surgery for AVSD is generally performed at 3–6 months of age, and if delayed, the opportunity for surgery may be lost owing to increased pulmonary vascular resistance (Eisenmenger syndrome). The prognosis of cardiac surgery in patients with Down syndrome is similar to or somewhat lower than in the general population, but outcomes have improved with recent advances in surgical technique.

Correction of gastrointestinal malformations

Duodenal atresia, esophageal malformations, Hirschsprung disease, etc. are corrected in the neonatal period or infancy according to their respective surgical indications. GERD is treated first with positioning, antacids, H2 blockers, or PPIs.

Endocrine and metabolic management

Hypothyroidism is treated with levothyroxine supplementation. Nutritional counseling and encouragement of physical activity are important for preventing obesity. The risk of developing diabetes is also higher than in the general population, so regular blood glucose monitoring is recommended.

Hematologic malignancy management

Transient abnormal myelopoiesis (TAM) mostly remits spontaneously, but in some it may progress to acute megakaryoblastic leukemia (AMKL, DS-AMKL). Monitoring for GATA1 gene mutations is recommended. DS-AMKL responds well to low-dose cytarabine and has a better prognosis than AMKL in general children.

Neurodevelopmental rehabilitation and education

Early intervention programs include speech therapy, occupational therapy, physical therapy, and special education. Evidence-based early intensive rehabilitation improves cognitive and functional outcomes. In adulthood as well, continued employment support, community integration, and mental health care are needed.

Management of Alzheimer disease

After age 40, Alzheimer's pathology begins to appear in almost all patients, and the incidence of clinical dementia rises sharply in the 50s and 60s. Use of acetylcholinesterase inhibitors (donepezil, rivastigmine) may be considered in some patients, but data from large Down syndrome-specific clinical trials are limited. Clinical trials of anti-amyloid therapy are currently under way in Down syndrome cohorts.


11. Prognosis

The prognosis of patients with Down syndrome has improved markedly over the past several decades. Unlike the 1960s, when average life expectancy was under 10 years, it has now extended to an average of 60 years or more. However, there are large differences between individuals depending on complications.

Causes of death and risk by age

The main causes of death in infancy and childhood are congenital heart disease, respiratory infections (recurrent pneumonia), and gastrointestinal malformations. From middle age onward, Alzheimer's disease emerges as the main cause of death. U.S. data report that about 75% of patients with Down syndrome survive to age 30 and about 50% to age 50.

Cognitive prognosis

Patients who receive early intervention and continued educational support show higher levels of function, and some are capable of semi-independent living and sheltered employment. However, once cognitive decline due to Alzheimer's pathology begins after the 40s, daily function can decline rapidly.

Prognosis after cardiac surgery

Patients who have successfully undergone corrective surgery for congenital heart disease have significantly improved life expectancy compared with patients who did not undergo surgery. The surgical prognosis depends on the type of cardiac malformation, the timing of surgery, and the level of pulmonary vascular resistance.

Mental health prognosis

Anxiety disorders, obsessive-compulsive disorder, and autism spectrum disorder accompany at a higher frequency than in the general population. Mental health support and monitoring in adolescence and adulthood have an important effect on quality of life.


12. Prevention

There is currently no method of preventing trisomy 21 itself. However, understanding of the mechanism of meiotic nondisjunction and advances in prenatal screening and diagnostic technology have greatly improved the clinical response.

Prenatal screening and counseling

For older pregnant women (aged 35 or older), NIPT or first-trimester combined screening is preferentially recommended. When the screening result is positive, genetic counseling is provided, with non-directive information about confirmation and the decision to continue the pregnancy. When there was a trisomy in a previous pregnancy or a parent is a carrier of a Robertsonian translocation (related to Q90.2), genetic counseling is provided in early pregnancy or at the pregnancy planning stage.

Folic acid supplementation

Although folic acid supplementation is established to be effective in preventing neural tube defects, a direct preventive effect on Down syndrome (nondisjunction mechanism) has not been established. Some studies have put forward the hypothesis that genetic variants related to methylation metabolism (MTHFR C677T, etc.) may increase the risk of nondisjunction, but confirmatory evidence is lacking.

Preimplantation genetic testing (PGT)

Performing preimplantation genetic testing for aneuploidy (PGT-A) during in vitro fertilization (IVF) to select euploid embryos is a preventive strategy that can be chosen by older pregnant women or patients with recurrent pregnancy loss. In Robertsonian translocation carriers, unbalanced translocation embryos can be excluded through PGT for structural rearrangement (PGT-SR).

Prevention of Down syndrome complications

After birth, efforts are made to prevent complications through completion of vaccinations (especially influenza, pneumococcal, and RSV prevention), thyroid function monitoring, regular ophthalmology and otolaryngology examinations, and oral health care. Maintaining a healthy diet and physical activity is important for preventing obesity and metabolic syndrome.


13. References

  1. Lejeune J, Gautier M, Turpin R. Étude des chromosomes somatiques de neuf enfants mongoliens. C R Acad Sci. 1959;248:1721–1722.
  2. Hassold T, Hunt P. To err (meiotically) is human: the genesis of human aneuploidy. Nat Rev Genet. 2001;2(4):280–291. doi:10.1038/35066065
  3. Orr B, Compton DA. A double-edged sword: how oncogenes and tumor suppressor genes can contribute to chromosomal instability. Front Oncol. 2013;3:164. doi:10.3389/fonc.2013.00164
  4. Nagaoka SI, Hassold TJ, Hunt PA. Human aneuploidy: mechanisms and new insights into an age-old problem. Nat Rev Genet. 2012;13(7):493–504. doi:10.1038/nrg3245
  5. Bull MJ; Committee on Genetics. Health supervision for children with Down syndrome. Pediatrics. 2011;128(2):393–406. doi:10.1542/peds.2011-1605
  6. Malt EA, Dahl RC, Haugsand TM, et al. Health and disease in adults with Down syndrome. Tidsskr Nor Laegeforen. 2013;133(3):290–294. doi:10.4045/tidsskr.12.0390
  7. Wiseman FK, Alford KA, Tybulewicz VL, Fisher EM. Down syndrome—recent progress and future prospects. Hum Mol Genet. 2009;18(R1):R75–R83. doi:10.1093/hmg/ddp010
  8. Patterson D. Molecular genetic analysis of Down syndrome. Hum Genet. 2009;126(1):195–214. doi:10.1007/s00439-009-0696-8
  9. Loane M, Morris JK, Addor MC, et al. Twenty-year trends in the prevalence of Down syndrome and other trisomies in Europe: impact of maternal age and prenatal screening. Eur J Hum Genet. 2013;21(1):27–33. doi:10.1038/ejhg.2012.94
  10. Strydom A, Shooshtari S, Lee L, et al. Dementia in older adults with intellectual disabilities—epidemiology, presentation, and diagnosis. J Policy Pract Intellect Disabil. 2010;7(2):96–110. doi:10.1111/j.1741-1130.2010.00253.x